Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: A multicenter study
Authors
Olives Nguyen, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Jack Wiedrick, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Daniele Massera, NYU Langone, New York, NY, USA.
Elizabeth Adlestein, NYU Langone, New York, NY, USA.
Sumar Frejat, NYU Langone, New York, NY, USA.
Matteo Castrichini, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
Said Alsidawi, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
John R. Giudicessi, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
Jeffrey B. Geske, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
Richard T. Carrick, Johns Hopkins University, Baltimore, MD, USA.
Jose Madrazo, Johns Hopkins University, Baltimore, MD, USA.
Nicole Dellise, Ascension Saint Thomas Heart West, Nashville, TN, USA.
Mark A. Zenker, Ascension Saint Thomas Heart West, Nashville, TN, USA.
Thomas A. Boyle, University of Pennsylvania, Philadelphia, PA, USA.
Nosheen Reza, University of Pennsylvania, Philadelphia, PA, USA.
Anjali Tiku Owens, University of Pennsylvania, Philadelphia, PA, USA.
David S. Frankel, University of Pennsylvania, Philadelphia, PA, USA.
Prabhjot Hundal, Advocate Health - MidwestFollow
Jamil Tajik, Advocate Health - MidwestFollow
Patrycja Galazka, Advocate Health - MidwestFollow
et al
Recommended Citation
Nguyen O, Wiedrick J, Massera D, et al. Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study. J Card Fail. Published online March 1, 2026. doi:10.1016/j.cardfail.2026.02.035
Affiliations
Aurora St. Luke's Medical Center